Sever Mehmet Sukru
Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2016 Nov 1;37(2-3):49-53. doi: 10.1515/prilozi-2016-0016.
The terminologies of "body size", "body mass index (BMI)", "body weight", "large BMI" and "obesity" are controversial for defining the effects of "adiposity" or "fat excess" on the outcomes of dialysis and transplant patients. However, probably these terminologies will be continued to be used in the future as well, because of being older and simpler terminologies. In the general population obesity is a powerful risk factor for cardiovascular morbidity and mortality, while, it conferred a survival advantage to dialysis patients. However, this may be a oversimplification, since obesity may still be a risk factor in non-sarcopenic hemodialysis patients. Obesity is associated with early post-transplant adverse effects (i.e. delayed graft function, graft failure, wound infections, also transplant costs) and unfavorable graft and patient survival. However, thanks to safer immunosuppressive protocols, recently graft and patient survival is similar in obese as those of the non-obese patients. On the other hand, morbid obesity may still be a cause of unfavorable patient and graft survival. Since obese transplant recipients have better life expectancy as compared to wait-listed hemodialysis patients, they should be transplanted as well, while morbidly obese patients should be asked to lose weight before being placed in the waiting lists.
“体型”“体重指数(BMI)”“体重”“高BMI”和“肥胖”等术语在定义“肥胖”或“脂肪过多”对透析和移植患者预后的影响方面存在争议。然而,由于这些术语使用时间较长且较为简单,未来可能仍会继续使用。在普通人群中,肥胖是心血管疾病发病和死亡的一个重要危险因素,而在透析患者中,肥胖却具有生存优势。然而,这可能过于简单化了,因为在非肌肉减少性血液透析患者中,肥胖可能仍是一个危险因素。肥胖与移植后早期不良反应(如移植肾功能延迟恢复、移植失败、伤口感染以及移植成本增加)以及移植器官和患者的不良生存情况相关。然而,由于免疫抑制方案更加安全,近年来肥胖患者和非肥胖患者的移植器官和患者生存率相似。另一方面,病态肥胖可能仍然是导致患者和移植器官不良生存的一个原因。由于与等待透析的患者相比,肥胖的移植受者预期寿命更长,他们也应该接受移植,而病态肥胖患者在进入等待名单之前应被要求减重。